芪苈强心胶囊联合伊伐布雷定治疗缺血性心肌病的效果

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (535 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Qili Qiangxin Capsules combined with Ivabradine in the treatment of ischemic cardiomyopathy (ICM). Methods Seventy ICM patients treated in Xintai Hospital of Traditional Chinese Medicine from June 2016 to June 2019 were selected and divided into control group and observation group according to random number table method, with 35 cases in each group. The two groups were given conventional treatment, on basis of which, the control group was given Qili Qiangxin Capsules and the observation group was given Qili Qiangxin Capsules combined with Ivabradine. The clinical effects of the two groups were compared and the changes of left heart function [peak ejection rate (PER), peak filling rate (PFR), left ventricular ejection fraction (LVEF) and left ventricular shortening fractional (LVSF)], autonomic nerve function [standard deviation of NN intervals (SDNN), standard deviation average of NN intervals (SDANN), root mean square of successive differences (rMSSD) of adjacent RR intervals, the proportion of successive RR intervals difference≥50 ms in percentage (pNN50), low-frequency/high-frequency (LF/HF)], related neuroendocrine factors [N-terminal pro-brain natriuretic peptide (NT-proBNP), cardiac troponin I (cTnI),] and myocardial enzymes [creatine kinase (CK), creatine kinase-MB (CK-MB)] were observed before and after treatment. Results The total effective rate in observation group was significantly higher than that in control group (P ＜ 0.05). After treatment, PER, PFR, LVEF and LVSF in both groups were higher than those before treatment (P ＜ 0.05). After treatment, LVEF and LVSF in observation group were higher than those in control group (P ＜ 0.05). After treatment, the levels of NT-proBNP, cTnI, CK and CK-MB in both groups were lower than those before treatment, and observation group were lower than those in control group (P ＜ 0.05). Compared with those before treatment, SDNN were increased in both groups, SDANN in observation group was significantly increased (P ＜ 0.05). After treatment, SDNN and SDANN in observation group were higher than those in control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between two groups (P ＞ 0.05). Conclusion Qili Qiangxin Capsules combined with Ivabradine is effective in the treatment of ICM, which can improve left heart function, regulate autonomic nerve function, adverse reaction is lower, and it is worthy of clinical promotion.

Key words： Qili Qiangxin Capsules Ivabradine Ischemic cardiomyopathy Clinical effect Autonomic nerve function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	SHI Xinxia LU Lu LU Yanhong

Cite this article:

SHI Xinxia LU Lu LU Yanhong. Effect of Qili Qiangxin Capsules combined with Ivabradine in the treatment of ischemic cardiomyopathy[J]. 中国医药导报, 2020, 17(23): 45-48.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I23/45

[1] 胡锋，陈婷.缺血性心肌病住院患者的临床特征、冠状动脉介入治疗效果和预后分析[J].中国心血管杂志，2019， 24（2）：115-120.
[2] 张琳，董智强，孙婷婷，等.缺血性心肌病的临床治疗分析[J].齐齐哈尔医学院学报，2016，37（11）：1426-1427.
[3] 张明卜，郭晨，李敏，等.伊伐布雷定在心血管疾病中的最新应用进展[J].心血管病学进展，2018，39（6）：1008-1012.
[4] 陈小东，周峻.芪苈强心胶囊与曲美他嗪在缺血性心肌病心力衰竭患者中的联合应用[J].中国实验方剂学杂志，2015，21（19）：171-175.
[5] 中华医学会心血管病学分会，中华心血管病杂志编辑委员会，中国心肌病诊断与治疗建议工作组.心肌病诊断与治疗建议[J].中华心血管病杂志，2007，35（1）：5-16.
[6] 郑筱萸.中药新药临床研究指导原则[M].北京：中国医药科技出版社，2002.
[7] 王苏媛，孟浩宇，蒋宏粉，等.缺血性心肌病和非缺血性心肌病病人远期心源性死亡事件的临床分析[J].中西医结合心脑血管病杂志，2019，17（23）：3781-3784.
[8] 朱王亮，宋剑，刘晶，等.缺血性心肌病的连续心率减速力与心率变异性研究[J].重庆医学，2018，47（9）：1273-1276.
[9] 陈雨，李海同，刘倩，等.左西孟旦联合芪苈强心胶囊对老年缺血性心肌病心力衰竭患者作用分析[J].河北医药，2018，40（15）：2256-2259.
[10] 国家卫生计生委合理用药专家委员会，中国药师协会.冠心病合理用药指南[J].中国医学前沿杂志：电子版，2016，8（6）：19-108.
[11] 袁梁宸.β受体阻滞剂在心血管疾病治疗中的临床研究进展[J].中国医药指南，2015，13（10）：58-59.
[12] 黎土娣，张仁丹.伊伐布雷定在冠心病患者中的应用进展[J].中国循环杂志，2018，33（5）：504-506.
[13] 罗良涛，赵慧辉，冯玄超，等.中医医院冠心病慢性心力衰竭患者临床流行病学调查[J].北京中医药大学学报，2013，36（9）：645-648.
[14] 董川.探析缺血性心肌病中医辨证施治的治疗效果[J].中国医药指南，2017，15（33）：219-220.
[15] 孙元隆，阮小芬，李益萍，等.辨证论治应用芪苈强心胶囊对缺血性心力衰竭疗效影响的Meta分析比较[J].中国中药杂志，2019，44（22）：4975-4984.
[16] 贾晓雅，石立鹏，劳闻文，等.芪苈强心胶囊治疗慢性心力衰竭机制研究进展[J].实用中医药杂志，2018，34（7）：878-879.
[17] 马柳一，尹玉洁，张军芳，等.芪苈强心胶囊对慢性心衰大鼠下丘脑室旁核RAS系统及交感神经系统的影响[J].中国药理学通报，2016，32（4）：575-580.
[18] 白成斌，郭亚妮.芪苈强心胶囊联合曲美他嗪治疗缺血性心肌病心力衰竭的效果[J].临床医学研究与实践，2019，4（10）：128-130.
[19] 陶玲，杜涛，缪金龙，等.芪苈强心胶囊对老年缺血性心肌病伴心力衰竭患者血浆NT-proBNP水平的影响[J].西部中医药，2015，28（8）：75-77.
[20] 高艳周，王宏斌，苗博，等.芪苈强心胶囊联合曲美他嗪治疗缺血性心肌病心力衰竭疗效观察[J].现代中西医结合杂志，2016，25（8）：845-847.